MX2017003470A - Inhibidores macrociclicos de cinasa lrrk2. - Google Patents
Inhibidores macrociclicos de cinasa lrrk2.Info
- Publication number
- MX2017003470A MX2017003470A MX2017003470A MX2017003470A MX2017003470A MX 2017003470 A MX2017003470 A MX 2017003470A MX 2017003470 A MX2017003470 A MX 2017003470A MX 2017003470 A MX2017003470 A MX 2017003470A MX 2017003470 A MX2017003470 A MX 2017003470A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- disease
- lrrk2 kinase
- compounds
- lrrk2
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 abstract 3
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279 | 2014-09-17 | ||
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003470A true MX2017003470A (es) | 2017-08-07 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003470A MX2017003470A (es) | 2014-09-17 | 2015-09-17 | Inhibidores macrociclicos de cinasa lrrk2. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (enExample) |
| EP (1) | EP3194405B1 (enExample) |
| JP (1) | JP2017529365A (enExample) |
| KR (1) | KR20170048599A (enExample) |
| CN (1) | CN107108641A (enExample) |
| AU (1) | AU2015316801B2 (enExample) |
| BR (1) | BR112017005299A2 (enExample) |
| CA (1) | CA2960777A1 (enExample) |
| DK (1) | DK3194405T3 (enExample) |
| EA (1) | EA032838B1 (enExample) |
| ES (1) | ES2717510T3 (enExample) |
| HU (1) | HUE043972T2 (enExample) |
| IL (1) | IL251054B (enExample) |
| MX (1) | MX2017003470A (enExample) |
| PL (1) | PL3194405T4 (enExample) |
| SG (1) | SG11201701936WA (enExample) |
| TR (1) | TR201904514T4 (enExample) |
| TW (1) | TW201625639A (enExample) |
| WO (1) | WO2016042089A1 (enExample) |
| ZA (1) | ZA201701841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| AR124556A1 (es) * | 2020-01-31 | 2023-04-12 | Oncodesign Sa | Inhibidores macrocíclicos de rip2-cinasa |
| CR20220561A (es) | 2020-05-06 | 2023-02-17 | Servier Lab | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 |
| MX2023010910A (es) | 2021-03-18 | 2023-09-27 | Servier Lab | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. |
| WO2023064768A1 (en) * | 2021-10-11 | 2023-04-20 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
| CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| AR130483A1 (es) | 2022-09-15 | 2024-12-11 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132486A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132487A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132488A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| RU2170082C2 (ru) | 1993-10-01 | 2001-07-10 | Астра Актиеболаг | Способ обработки лекарственного средства, устройство для формирования лекарственного средства и лекарственное средство |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| CN1274690C (zh) | 2000-12-28 | 2006-09-13 | 小野药品工业株式会社 | 三杂环化合物和包括其作为活性组分的药物 |
| US7067507B2 (en) * | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| ES2393926T3 (es) | 2004-10-21 | 2013-01-02 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gen KASPP (LRRK2), su producción y uso para la detección y tratamiento de trastornos neurodegenerativos |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| CN101365703B (zh) | 2005-11-16 | 2013-11-06 | S*Bio私人有限公司 | 杂烷基连接的嘧啶衍生物 |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| ES2512727T3 (es) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | Nuevos compuestos |
| SMT201700372T1 (it) * | 2010-05-20 | 2017-09-07 | Array Biopharma Inc | Composti macrociclici come inibitori di trk chinasi |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| HUE027318T2 (en) * | 2011-09-30 | 2016-10-28 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
| PL2760453T3 (pl) | 2011-09-30 | 2016-11-30 | Makrocykliczne Inhibitory kinazy LRRK2 |
-
2015
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 PL PL15766801T patent/PL3194405T4/pl unknown
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016042089A1 (en) | 2016-03-24 |
| HUE043972T2 (hu) | 2019-09-30 |
| PL3194405T3 (pl) | 2019-07-31 |
| DK3194405T3 (en) | 2019-04-15 |
| ES2717510T3 (es) | 2019-06-21 |
| AU2015316801B2 (en) | 2019-03-07 |
| EP3194405A1 (en) | 2017-07-26 |
| ZA201701841B (en) | 2019-08-28 |
| PL3194405T4 (pl) | 2019-07-31 |
| SG11201701936WA (en) | 2017-04-27 |
| JP2017529365A (ja) | 2017-10-05 |
| US20170240565A1 (en) | 2017-08-24 |
| EP3194405B1 (en) | 2018-12-26 |
| KR20170048599A (ko) | 2017-05-08 |
| AU2015316801A1 (en) | 2017-04-27 |
| EA201790626A1 (ru) | 2017-07-31 |
| TR201904514T4 (tr) | 2019-04-22 |
| IL251054A0 (en) | 2017-04-30 |
| IL251054B (en) | 2019-03-31 |
| BR112017005299A2 (pt) | 2017-12-12 |
| US10377772B2 (en) | 2019-08-13 |
| TW201625639A (zh) | 2016-07-16 |
| CA2960777A1 (en) | 2016-03-24 |
| CN107108641A (zh) | 2017-08-29 |
| EA032838B1 (ru) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017003470A (es) | Inhibidores macrociclicos de cinasa lrrk2. | |
| MX342177B (es) | Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. | |
| PH12016501307A1 (en) | Compounds | |
| UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
| MX368781B (es) | Compuesto inhibidor de las actividades de las cinasas btk y/o jak3. | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| SG179120A1 (en) | Novel compounds | |
| MX2012001070A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos. | |
| UA118610C2 (uk) | Спіроциклічні інгібітори катепсину c | |
| MY199446A (en) | Compounds and compositions and uses thereof | |
| MX2015011359A (es) | Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2). | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| MX2015012528A (es) | Inhibidores macrociclicos de cinasa inducibles por sal. | |
| MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| MY186523A (en) | Macrocyclic rip2 kinase inhibitors | |
| EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| GB2553685A (en) | Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| TN2011000668A1 (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |